ATE229945T1 - Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole - Google Patents

Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole

Info

Publication number
ATE229945T1
ATE229945T1 AT99912221T AT99912221T ATE229945T1 AT E229945 T1 ATE229945 T1 AT E229945T1 AT 99912221 T AT99912221 T AT 99912221T AT 99912221 T AT99912221 T AT 99912221T AT E229945 T1 ATE229945 T1 AT E229945T1
Authority
AT
Austria
Prior art keywords
treatment
cmv infections
thiadiazoles
cmv
thiadiazoles suitable
Prior art date
Application number
AT99912221T
Other languages
English (en)
Inventor
Steven R Turner
Suvit Thaisrivongs
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE229945T1 publication Critical patent/ATE229945T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT99912221T 1998-03-19 1999-03-16 Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole ATE229945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7852898P 1998-03-19 1998-03-19
PCT/US1999/003744 WO1999047507A2 (en) 1998-03-19 1999-03-16 1,3,4-thiadiazoles useful for the treatment of cmv infections

Publications (1)

Publication Number Publication Date
ATE229945T1 true ATE229945T1 (de) 2003-01-15

Family

ID=22144610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912221T ATE229945T1 (de) 1998-03-19 1999-03-16 Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole

Country Status (11)

Country Link
US (1) US6150385A (de)
EP (1) EP1064273B1 (de)
JP (1) JP2002506858A (de)
AT (1) ATE229945T1 (de)
AU (1) AU743489B2 (de)
CA (1) CA2320167A1 (de)
DE (1) DE69904576T2 (de)
DK (1) DK1064273T3 (de)
ES (1) ES2189404T3 (de)
NZ (1) NZ507032A (de)
WO (1) WO1999047507A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539119A (ja) 1999-03-08 2002-11-19 バイエル アクチェンゲゼルシャフト チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
AU2002364549B2 (en) * 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
NZ545265A (en) 2003-07-30 2009-11-27 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AR051026A1 (es) * 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
AU2006235759B2 (en) * 2005-04-06 2011-07-28 Msd K.K. 1,4-substituted piperazine derivative
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
AU2007288245A1 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
CN102083427B (zh) * 2008-01-09 2014-12-10 分子洞察制药公司 碳酸酐酶ix的抑制剂
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
US8465725B2 (en) 2009-06-15 2013-06-18 Molecular Insight Pharmaceuticlas, Inc. Process for production of heterodimers of glutamic acid
JP2013526544A (ja) 2010-05-12 2013-06-24 ヴァンダービルト ユニバーシティー 複素環スルホンmGluR4アロステリック増強剤、組成物、および神経機能不全を治療する方法
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
CA2860504A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
EP2914588B1 (de) 2012-11-03 2016-09-14 Boehringer Ingelheim International GmbH Inhibitoren des cytomegalovirus
CA2897437C (en) 2013-01-14 2021-12-14 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
AR108175A1 (es) 2016-04-06 2018-07-25 Innovative Molecules Gmbh Compuestos antivíricos de tiazol acetamida
EP4209491A1 (de) 2017-10-05 2023-07-12 Innovative Molecules GmbH Enantiometer einer reihe antiviraler verbindungen
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
CN114667285B (zh) 2019-09-26 2025-08-08 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
CN117695281B (zh) * 2023-12-26 2024-06-21 广州医科大学 四氢喹啉酮-酰胺-噻唑类化合物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8148047A0 (it) * 1981-03-18 1981-03-18 Manetti & Roberts Italo Brit Composti organici derivati da 2-ami no-5-(o-solfamidofenil)-1,3,4-tiadiazolo loro applicazione terapeutica e procedimento per la loro preparazione
SU1678206A3 (ru) * 1985-12-16 1991-09-15 Эли Лилли Энд Компани (Фирма) Способ получени 1, 3, 4-тиадиазол-2-цианамида или его фармацевтически приемлемых солей
AU3886493A (en) * 1992-04-22 1993-11-18 Karin Elisabeth Peuschel Immuno-activating and hence anti-viral effect of 4-{3-(subst.-amino)-2-hydroxypropoxy}-1,2,5-thiadiazole compounds
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5948916A (en) * 1994-09-22 1999-09-07 Rational Drug Design Laboratories Arylthiadiazole derivative and antiviral agent containing the same

Also Published As

Publication number Publication date
WO1999047507A2 (en) 1999-09-23
EP1064273B1 (de) 2002-12-18
US6150385A (en) 2000-11-21
CA2320167A1 (en) 1999-09-23
DE69904576T2 (de) 2003-07-10
AU3063999A (en) 1999-10-11
DE69904576D1 (de) 2003-01-30
NZ507032A (en) 2003-06-30
WO1999047507A3 (en) 1999-12-09
AU743489B2 (en) 2002-01-24
EP1064273A2 (de) 2001-01-03
DK1064273T3 (da) 2003-03-31
JP2002506858A (ja) 2002-03-05
ES2189404T3 (es) 2003-07-01

Similar Documents

Publication Publication Date Title
ATE229945T1 (de) Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
EA200000840A1 (ru) Антивирусные производные пиримидина
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
AU7713891A (en) Use of substituted 1,2,4-triazinediones
HU9303680D0 (en) Inhibitors of hiv protease useful for the treatment of aids
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
FI935779L (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
PY0101564A (es) Triazine containing anionic compounds useful as antiviral agents
CY1112574T1 (el) Οκταπεπτιδιο το οποιο εχει αντιαγγειογενετικη δραστικοτητα
ECSP972314A (es) Derivados de aminoacidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064273

Country of ref document: EP

REN Ceased due to non-payment of the annual fee